Extract
The structure and composition of the bronchial epithelium is altered in respiratory diseases such as COPD and asthma, in which goblet cell hyperplasia and reduced numbers of ciliated cells impair mucociliary clearance. Current standard of care focuses on alleviating disease symptoms, such as airway obstruction and inflammation, using bronchodilators or steroids, respectively. Whilst these approaches are effective, they do not address the underlying pathogenic processes. An alternative way forward would be to identify and target the dysregulated cellular pathways responsible for impaired bronchial epithelial function. In this study we describe a single-step, highly efficient and easily scalable genome editing pipeline to aid the dissection of the molecular mechanisms underlying primary human bronchial epithelial cell (BEC) differentiation and function at air–liquid interface (ALI).
Abstract
A single-step, highly efficient CRISPR/Cas9-based genome editing pipeline allows the dissection of the molecular mechanisms underlying primary human bronchial epithelial cell differentiation and function at the air-liquid interface http://bit.ly/2Oymgkw
Footnotes
Conflict of interest: R. Rapiteanu has nothing to disclose.
Conflict of interest: T Karagyozova has nothing to disclose.
Conflict of interest: N. Zimmermann has nothing to disclose.
Conflict of interest: K. Singh has nothing to disclose.
Conflict of interest: G. Wayne has nothing to disclose.
Conflict of interest: M. Martufi has nothing to disclose.
Conflict of interest: N.N. Belyaev has nothing to disclose.
Conflict of interest: E.M. Hessel is an employee of GlaxoSmithKline.
Conflict of interest: D. Michalovich is an employee of GSK and shareholder.
Conflict of interest: R. Macarron has nothing to disclose.
Conflict of interest: W.C. Rowan has nothing to disclose.
Conflict of interest: W.J. Cairns has nothing to disclose.
Conflict of interest: J. Roger has nothing to disclose.
Conflict of interest: J. Betts has nothing to disclose.
Conflict of interest: S. Beinke has nothing to disclose.
Conflict of interest: K. Maratou has nothing to disclose.
- Received February 1, 2019.
- Accepted January 31, 2020.
- Copyright ©ERS 2020